



Dr Vacis Tatarūnas is a chief researcher at the Laboratory of Molecular Cardiology, Institute of Cardiology, Lithuanian University of Health Sciences (LUHS). He is also a lecturer at the Department of Drug Chemistry, Faculty of Pharmacy, LUHS. In 2012, Vacis Tatarūnas defended his doctoral dissertation 'Research of Genetic Factors in Individualization of Anticoagulant and Antiplatelet Therapy: Pharmacogenetics of Warfarin and Clopidogrel'. The aim of his current research is to identify clinically important biomarkers that determine the individualization of the treatment with drugs affecting the activity of the blood coagulation system by investigating the links of inflammatory processes in patients with cardiovascular disease. From 2010 to 2020, he published 17 articles in journals referenced in the database Web of Science (Clarivate Analytics). Dr Tatarūnas participates in science popularization activities, collaborates with foreign scientists on the topic of drug individualization, and presents his work in Lithuania and at international conferences. He is currently leading one research project coordinated by the Research Council of Lithuania. Since 2010, he has been one of the main researchers of two research projects and has led two projects coordinated by the Research Council of Lithuania. Vacis Tatarūnas has participated in joint projects of Kaunas University of Technology and LUHS, also in projects of LUHS and business entities. From 2012 to 2016, he was an expert in the Pharmacogenomics Working Group (EMA PGWP) of the European Medicines Agency. Since 2012, he has been a member of the International Society for Thrombosis and Hemostasis (ISTH). Since 2015, Dr Tatarūnas is the chair of the Fundamental Sciences Working Group of the Lithuanian Society of Cardiology.